134 related articles for article (PubMed ID: 1692938)
1. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
4. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
Kronbach T
Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
[No Abstract] [Full Text] [Related]
5. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.
Dayer P; Leemann T; Striberni R
Clin Pharmacol Ther; 1989 Jan; 45(1):34-40. PubMed ID: 2910636
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
8. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
9. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
10. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
12. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
13. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Masimirembwa CM; Hasler JA; Johansson I
Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
[TBL] [Abstract][Full Text] [Related]
16. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
Broly F; Vandamme N; Libersa C; Lhermitte M
Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
[TBL] [Abstract][Full Text] [Related]
18. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
[TBL] [Abstract][Full Text] [Related]
19. Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Tyndale RF; Gonzalez FJ; Hardwick JP; Kalow W; Inaba T
Pharmacol Toxicol; 1990 Jul; 67(1):14-8. PubMed ID: 2395811
[TBL] [Abstract][Full Text] [Related]
20. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
